nortriptyline has been researched along with Somatoform Disorders in 4 studies
Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.
nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.
Somatoform Disorders: Disorders having the presence of physical symptoms that suggest a general medical condition but that are not fully explained by another medical condition, by the direct effects of a substance, or by another mental disorder. The MEDICALLY UNEXPLAINED SYMPTOMS must cause clinically significant distress or impairment in social, occupational, or other areas of functioning. In contrast to FACTITIOUS DISORDERS and MALINGERING, the physical symptoms are not under voluntary control. (APA, DSM-V)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among 811 adults with moderate-to-severe depression, melancholic, atypical, anxious and anxious-somatizing depression subtypes established at baseline were evaluated as predictors of outcome of treatment with flexible dosage of the SSRI escitalopram or the tricyclic antidepressant nortriptyline." | 2.76 | Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline. ( Aitchison, KJ; Dernovsek, MZ; Farmer, A; Hauser, J; Henigsberg, N; Kalember, P; Maier, W; McGuffin, P; Mendlewicz, J; Mors, O; Placentino, A; Rietschel, M; Souery, D; Uher, R; Zobel, A, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Uher, R | 1 |
| Dernovsek, MZ | 1 |
| Mors, O | 1 |
| Hauser, J | 1 |
| Souery, D | 1 |
| Zobel, A | 1 |
| Maier, W | 1 |
| Henigsberg, N | 1 |
| Kalember, P | 1 |
| Rietschel, M | 1 |
| Placentino, A | 1 |
| Mendlewicz, J | 1 |
| Aitchison, KJ | 1 |
| McGuffin, P | 1 |
| Farmer, A | 1 |
| Brown, C | 1 |
| Schulberg, HC | 1 |
| Madonia, MJ | 1 |
| Sullivan, M | 1 |
| Katon, WJ | 2 |
| Russo, J | 1 |
| Dobie, R | 1 |
| Sakai, C | 1 |
| Walker, EA | 1 |
| Roy-Byrne, PP | 1 |
| Jemelka, R | 1 |
3 trials available for nortriptyline and Somatoform Disorders
| Article | Year |
|---|---|
Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety Disorders | 2011 |
Clinical presentations of major depression by African Americans and whites in primary medical care practice.
Topics: Adolescent; Adult; Antidepressive Agents, Tricyclic; Attitude to Health; Black or African American; | 1996 |
Somatization, co-morbidity, and the quality of life: measuring the effect of depression upon chronic medical illness.
Topics: Activities of Daily Living; Audiometry, Pure-Tone; Chronic Disease; Comorbidity; Depressive Disorder | 1992 |
1 other study available for nortriptyline and Somatoform Disorders
| Article | Year |
|---|---|
An open trial of nortriptyline in women with chronic pelvic pain.
Topics: Abdominal Pain; Adult; Chronic Disease; Female; Genital Diseases, Female; Humans; Nortriptyline; Pat | 1991 |